232 related articles for article (PubMed ID: 33895011)
41. Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
Penny CL; Quow K; Rundle CW; Al-Rohil RN; Cardones AR; Kheterpal MK; Fresco AI
Br J Dermatol; 2022 Jul; 187(1):126-127. PubMed ID: 35048357
[TBL] [Abstract][Full Text] [Related]
42. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
[TBL] [Abstract][Full Text] [Related]
43. Editorial Comment to Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
Miyata Y; Matsuo T
Int J Urol; 2022 Jul; 29(7):655. PubMed ID: 35355328
[No Abstract] [Full Text] [Related]
44. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
Chang E; Weinstock C; Zhang L; Charlab R; Dorff SE; Gong Y; Hsu V; Li F; Ricks TK; Song P; Tang S; Waldron PE; Yu J; Zahalka E; Goldberg KB; Pazdur R; Theoret MR; Ibrahim A; Beaver JA
Clin Cancer Res; 2021 Feb; 27(4):922-927. PubMed ID: 32962979
[TBL] [Abstract][Full Text] [Related]
45. Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date.
Moussa M; Papatsoris A; Abou Chakra M; Dellis A
Drug Des Devel Ther; 2021; 15():453-462. PubMed ID: 33603337
[TBL] [Abstract][Full Text] [Related]
46. Enfortumab Vedotin Checks Urothelial Cancer.
Cancer Discov; 2019 Oct; 9(10):OF1. PubMed ID: 31519705
[TBL] [Abstract][Full Text] [Related]
47. Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma.
Wu S; Adamson AS
Dermatol Online J; 2019 Feb; 25(2):. PubMed ID: 30865407
[TBL] [Abstract][Full Text] [Related]
48. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
Halford Z; Anderson MK; Clark MD
Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
[TBL] [Abstract][Full Text] [Related]
49. Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Tilgener C; Bedke J
Eur Urol; 2024 Jun; 85(6):591-592. PubMed ID: 38538421
[No Abstract] [Full Text] [Related]
50. Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
Goto Y
Int J Urol; 2023 Sep; 30(9):704. PubMed ID: 36482811
[No Abstract] [Full Text] [Related]
51. Enfortumab vedotin in the treatment of urothelial cancers and beyond.
Wong RL; Yu EY
Future Oncol; 2022 Sep; 18(27):3067-3084. PubMed ID: 36004667
[TBL] [Abstract][Full Text] [Related]
52. Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
Taguchi S; Kawai T; Nakagawa T; Kume H
BJU Int; 2024 Jul; 134(1):43-44. PubMed ID: 38073020
[No Abstract] [Full Text] [Related]
53. The future of drug development in urothelial cancer.
Dreicer R
J Clin Oncol; 2012 Feb; 30(5):473-5. PubMed ID: 22184400
[No Abstract] [Full Text] [Related]
54. Cutaneous and Renal Toxicities of Enfortumab Vedotin for Advanced Urothelial Carcinoma: The UROKYU Study.
Furubayashi N; Minato A; Tomoda T; Masaoka H; Hori Y; Kiyoshima K; Negishi T; Haraguchi Y; Koga T; Song Y; Harada K; Kuroiwa K; Seki N; Fujimoto N; Nakamura M;
Anticancer Res; 2024 Jul; 44(7):3025-3032. PubMed ID: 38925809
[TBL] [Abstract][Full Text] [Related]
55. Editorial Comment to Enfortumab vedotin versus platinum rechallenge in post-platinum post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
Hashimoto T
Int J Urol; 2023 Dec; 30(12):1186-1187. PubMed ID: 37885321
[No Abstract] [Full Text] [Related]
56. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
57. Antibody-Drug Conjugates in Urothelial Carcinomas.
Sarfaty M; Rosenberg JE
Curr Oncol Rep; 2020 Feb; 22(2):13. PubMed ID: 32008109
[TBL] [Abstract][Full Text] [Related]
58. New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?
Hoffman-Censits J; Lombardo K; McConkey D; Hahn NM; Bashir B; Kelly WK; Johnson B; Matoso A
Urol Oncol; 2021 Oct; 39(10):619-622. PubMed ID: 34148797
[TBL] [Abstract][Full Text] [Related]
59. In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity.
Molina GE; Schwartz B; Srinivas S; Shah S; Zaba LC
Eur Urol; 2023 Apr; 83(4):377-378. PubMed ID: 36623949
[No Abstract] [Full Text] [Related]
60. [Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zschäbitz S; Niegisch G
Urologe A; 2020 Jul; 59(7):804-809. PubMed ID: 32472222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]